Ontario reports 1st death of rare blood clots linked to AstraZeneca, 2,485 new COVID-19 cases over 2 days

Ontario has reported its first death of a person who had rare blood clots after receiving a dose of the AstraZeneca-Oxford vaccine. The province has confirmed another 2,485 cases of COVID-19 over the last two days, as well as another 41 deaths linked to the illness.

Province reported 41 more deaths Sunday and Monday

Switch Health nurse Samantha Edgar prepares a does of the Pfizer-BioNTech COVID-19 vaccine at a clinic in Mississauga earlier this month. (Evan Mitsui/CBC)

Ontario has reported its first death of a person who developed rare blood clots after receiving a first dose of the AstraZeneca-Oxford vaccine.

It was one of 41 deaths linked to COVID-19 reported on Tuesday. Dr. Barbara Yaffe, the province's associate medical officer of health, said the person who died was a man in his 40s who had received his first dose in late April. He died a few weeks later.

Yaffe said the man was confirmed to have a rare but serious condition called vaccine-induced thrombotic thrombocytopenia (VITT).

"While the investigation is ongoing and a final cause of death has yet to be officially determined, it has been confirmed that the individual did have VITT at the time of his death," she said.

"Again, the risks associated with this vaccine are rare, but they are real," she added.

"I want to extend my deepest and heartfelt sympathies to the family and friends of this individual in the wake of this tragic death."

Yaffe said the province has seen 16 cases of serious blood clots known as thrombotic thrombocytopenic syndrome (TTS) linked to the AstraZeneca/COVISHIELD vaccine.

Thirteen of those cases meet the criteria for VITT.

"I want to take this opportunity to reiterate that those who received AstraZeneca vaccines should feel confident in their decision. Of course, if you have any questions of concerns, do not hesitate to reach out to your health-care provider," she said.

Nearly one million people in Ontario aged 40 and older have received the AstraZeneca vaccine.

Ontario stopped giving out first doses of AstraZeneca earlier this month after what it said was an increased risk of the rare blood clots associated with the vaccine.

The Ontario death is the fifth fatal case of VITT in an AstraZeneca recipient in Canada. Experts maintain the syndrome is exceedingly rare and treatable in most cases.

Testing levels low over long weekend

The province also confirmed another 2,485 cases of COVID-19 over the last two days.

Because of the Victoria Day long weekend, the province provided two days worth of data Tuesday morning.

The new cases break down to 1,446 on Sunday and 1,039 on Monday.

As expected, overall testing levels were quite low through the holiday weekend, with just over 37,000 total tests completed in the same two-day period. That said, positivity rates continued on a downward trend, suggesting that even with less testing, there are indeed fewer new cases occurring in the province compared to recent weeks. 

The seven-day average of daily cases fell to 1,693, its lowest point in more than eight weeks.

There are currently about 19,026 active COVID-19 infections provincewide, the fewest since March 29.

As of Monday evening, there were 692 people being treated for COVID-related illnesses in intensive care units. Of those, 498, or about 72 per cent, required a ventilator to breathe. 

Yaffe said the province is seeing improvement in the number of hospitalizations and people in ICUs.

"These trends remain encouraging, but the numbers are still very high. They represent people who are very ill from this disease," Yaffe said.

The additional deaths pushed the official toll to 8,655.

Public health units collectively administered 186,035 more doses of COVID-19 vaccines in the same timeframe. A total of 8,251,642 shots have been given out so far and about 64.3 per cent of Ontarians aged 18 and over have had at least one dose.

In Toronto, nearly two million shots have been administered to date, with the city saying more than 65 per cent of eligible adults have received at least one dose.

Some AstraZeneca vaccine available for 2nd shots

Meanwhile, Ontarians who received a first dose of the AstraZeneca COVID-19 vaccine in mid-March will be able to book their second shot this week as the province seeks to use up its stockpile before it expires.

Those who received a first shot from March 10 to March 19 are being prioritized for a second. Those dates encompass a pilot project that saw the AstraZeneca vaccine administered through pharmacies in Toronto, Kingston and Windsor, as well as through some primary care providers.

Though the recommended interval between shots is at least 12 weeks, the second injection is being offered to that group after 10 weeks in order to make use of 45,000 doses set to expire in roughly a week. Another 10,000 doses of AstraZeneca are due to expire next month.

Ontario currently has more than 300,000 doses in stock after a significant shipment arrived last week. 

The province has said those who got their first dose of AstraZeneca after March 19 will be able to book their second in the near future, but no additional details have been provided so far.

Ontarians who received a first dose of the AstraZeneca COVID-19 vaccine in mid-March will be able to book their second shot this week as the province seeks to use up its stockpile before it expires. (Valentina Petrova/The Associated Press)

Province publishes list of pharmacies with AZ for 2nd shots

Late in the day on Tuesday, the province published the list of 162 pharmacies administering soon-to-expire doses this week.

The head of the Ontario Pharmacists Association said a handful of pharmacies received doses on Tuesday, but the "vast majority" would receive supply on Wednesday.

Justin Bates said pharmacists would reach out to clients directly.

Bates said some of the 325 pilot locations were unable to participate due to the short window of time and other ongoing vaccinations.

Pharmacies are aiming to dispense the supply within five days to avoid wastage. The holiday Monday complicated some of the logistics, as many stores were closed, Bates said, and pharmacies are working to reach clients and manage the excess demand from eligible people.

"There's a lot to manage there from an administrative perspective," Bates said.

"Yes, it's going to be a challenge and we're up for it and we're going to do everything we can to hopefully achieve that success."

About 90,000 people are eligible to receive their second AstraZeneca vaccine at the shortened 10-week interval, according to provincial data — about double the number of doses available.

Bates said more doses will be on the way once those expiring May 31 are used up.

Dr. David Williams, Ontario's chief medical officer of health, said the province is working to prioritize pharmacies in the Toronto, Kingston and Windsor areas — where the initial pilot ran — for the second doses (Nathan Denette/The Canadian Press)

Dr. David Williams said the province is working to prioritize pharmacies in the Toronto, Kingston and Windsor areas — where the initial pilot ran — for the second doses.

He said people should talk to their pharmacists about eligibility and some might have to wait the original 12 weeks after the province has used up the soon-to-expire vaccines.

"I understand there's a bit of confusion there," Williams said. "The good point is that we have lots of people who are looking eager to get their second dose."

A spokeswoman for the health minister said many pharmacies and doctors would reach out to patients directly, and asked people to only contact participating pharmacies listed on the province's booking website.

AstraZeneca has been linked to rare, potentially fatal blood clots that are thought to occur at a rate of one in every 55,000 or so doses on the first shot, and one in 600,000 doses for the second.

With files from The Canadian Press


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?